Showing 8,581 - 8,600 results of 9,629 for search 'significantly ((((((lower decrease) OR (larger decrease))) OR (we decrease))) OR (linear decrease))', query time: 0.44s Refine Results
  1. 8581

    Image_1_Prognostic value of the Naples Prognostic Score in adult chronic obstructive pulmonary disease: NHANES 2005–2018.TIFF by Yue Kang (427523)

    Published 2024
    “…</p>Methods<p>A total of 15,184 participants were included in our research, and statistical analyses were performed after weighting. We used weighted logistic regression to assess whether the NPS and COPD had a relationship, as well as its association with lung function. …”
  2. 8582

    Supplementary Material for: Long-term outcomes and clinical factors associated with conventional therapy failure in intestinal Behçet’s disease: A retrospective cohort study in Jap... by figshare admin karger (2628495)

    Published 2025
    “…Concomitant glucocorticoid use significantly decreased from 12.7±11.7 mg/day at baseline to 2.4±2.5 mg/day at 1 year (p<0.001). …”
  3. 8583

    The epidemiology and gene mutation characteristics of pyrazinamide-resistant <i>Mycobacterium tuberculosis</i> clinical isolates in Southern China by Nan Wang (21935)

    Published 2025
    “…To fulfil these goals, we analyzed the phenotypic PZA resistance characteristics of 14,927 clinical isolates for which Bactec MGIT 960 PZA drug susceptibility testing (DST) results were available, revealing that 2,054 (13.76%) isolates were resistant to PZA. …”
  4. 8584

    Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  5. 8585

    Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  6. 8586

    Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  7. 8587

    Table 2_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.docx by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  8. 8588

    Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  9. 8589

    Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  10. 8590

    Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  11. 8591

    Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  12. 8592

    Table 2_Building radiomics models based on ACR TI-RADS combining clinical features for discriminating benign and malignant thyroid nodules.docx by Xingxing Chen (1569277)

    Published 2025
    “…To evaluate the clinical utility of the nomogram in reducing unnecessary biopsies, we further analyzed the performance of our integrated model (Clin+ACR+Rad) compared to the traditional ACR TI-RADS system at different probability thresholds. …”
  13. 8593

    Table_1_Unraveling the key mechanisms of Gastrodia elata continuous cropping obstacles: soil bacteria Massilia, Burkholderia-Caballeronia-Paraburkholderia, and Dyella along with so... by Mingzheng Duan (11630632)

    Published 2024
    “…However, continuous cropping of this species has led to various obstacles, such as microbial disease and pest infestation, significantly affecting the production and development of valuable medicinal and food resources. …”
  14. 8594

    Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  15. 8595

    Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  16. 8596

    Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  17. 8597

    Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  18. 8598

    Data Sheet 6_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  19. 8599

    Data Sheet 4_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  20. 8600

    Data Sheet 3_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”